Why The Narrative That Healthcare Is Built To Harm Women Is Completely Wrong

Why The Narrative That Healthcare Is Built To Harm Women Is Completely Wrong

The industry loves a villain. Right now, the favorite bad guy is a medical establishment supposedly engineered by misogynists to ignore, gaslight, and maim female patients. Turn on any news feed, read any think-piece, and you will find the same lazy consensus: women receive inferior care because the system hates them.

It is a neat narrative. It fits neatly on social media, triggers righteous anger, and demands zero intellectual heavy lifting.

It is also completely wrong.

I have spent years watching capital allocation, clinical trials, and reimbursement models from the inside. I have seen billions poured into dead ends because institutional players were too terrified of political backlash to look at actual data. The crisis in women's health is not a conspiracy of male malice. It is a compounding disaster born of regulatory cowardice, junk epidemiology, bad trial design, and an obsession with activist narratives over hard biology.

If we keep blaming cartoonish sexism, women will keep getting sick while the people with the microphones pat themselves on the back for being angry.

The Myth Of The Exclusionary Baseline

The foundation of the modern grievance is that medical science uses the male body as the default standard, leaving women as an afterthought. Activists point out that until 1993, women of childbearing potential were systematically excluded from phase one clinical trials by FDA decree.

They treat this as proof of historic hatred. They miss the actual reason.

The exclusion rule was a direct reaction to the thalidomide tragedy of the late 1950s and early 1960s. Regulators were terrified of fetal teratogenicity—unforeseen birth defects caused by investigational drugs interacting with early-stage pregnancies. The rule was born out of an abundance of liability-driven caution, not a desire to benefit men at the expense of women.

When researchers finally brought women back into early-phase trials, they ran straight into a biological variable that ruined clean spreadsheets: the estrous cycle.

Male biology is boringly linear. Female biology is a dynamic endocrine symphony. Hormonal fluctuations across a twenty-eight-day cycle alter pharmacokinetics, drug clearance rates, liver enzyme expression, and neurological baselines. If you run a phase one trial with a mixed cohort without controlling for cycle phase, your standard deviation blows up. Your statistical power vanishes.

Instead of solving this engineering problem by funding massive, properly powered trials that accounted for hormonal stratification, pharmaceutical companies took the path of least resistance. They kept testing on men because men were cheap, clean variables.

That is not malice. That is lazy corporate finance combined with regulatory paralysis. Blaming it on deep-seated hatred lets the FDA and big pharma off the hook for choosing convenience over rigor.

Why Chronic Pain Protocols Fail Everyone

Another pillar of the activist

CT

Claire Turner

A former academic turned journalist, Claire Turner brings rigorous analytical thinking to every piece, ensuring depth and accuracy in every word.